Zobrazeno 1 - 10
of 68
pro vyhledávání: '"D. Büchser"'
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 45, Iss , Pp 100733- (2024)
The utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost in prostate cancer treatment is a subject of ongoing debate and evolving clinical practice. While contemporar
Externí odkaz:
https://doaj.org/article/a453838328104490a4f2932fff6e1f6d
Autor:
A. Gomez-Iturriaga, D. Büchser, I. San Miguel, M. Marban, A. Urresola, A. Ezquerro, A. Gil, F. Suarez, A. Gonzalez, E. Mairata, L. Martinez-Indart, J. Cacicedo, F. Couñago, P. Mínguez, F. Casquero
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 24, Iss , Pp 135-139 (2020)
MRI-detected T3a prostate cancer is a heterogeneous disease. This post-hoc analysis of a prospective trial found that patients with T3a disease presenting obliteration of the recto-prostatic angle, contact-asymmetry of neuro-vascular bundle and perip
Externí odkaz:
https://doaj.org/article/600dde2f11414d31990be60fe4765883
Autor:
Alba González, Francisco Casquero, D. Büchser, Jose Maria Espinosa, F. Suarez, E. Mayrata, Pablo Mínguez, Jon Cacicedo, Iñigo San Miguel, Alfonso Gomez-Iturriaga, Jose Fernando Perez
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 13, Iss 1, Pp 12-17 (2021)
Journal of Contemporary Brachytherapy
Journal of Contemporary Brachytherapy
Purpose To evaluate toxicity, prostate-specific antigen (PSA) kinetics, and cancer control of high-dose-rate brachytherapy (HDR-BT) as a salvage modality for men with locally recurrent prostate cancer, after primary HDR-BT failure. Material and metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7671090785e1ac038b4352adfadaad5b
https://www.termedia.pl/Salvage-brachytherapy-for-locally-recurrent-prostate-cancer-after-single-fraction-19-Gy-high-dose-rate-brachytherapy-toxicity-prostate-specific-antigen-kinetics-and-cancer-control,54,43289,1,1.html
https://www.termedia.pl/Salvage-brachytherapy-for-locally-recurrent-prostate-cancer-after-single-fraction-19-Gy-high-dose-rate-brachytherapy-toxicity-prostate-specific-antigen-kinetics-and-cancer-control,54,43289,1,1.html
Autor:
Guillermo Celada, D. Büchser, M.T. Murillo, Almudena Zapatero, Carmen Martín de Vidales, Saturnino González, Pablo Rodríguez, M. Roch, Pablo Castro Tejero, Luis Alberto San Jose
Publikováno v:
Br J Radiol
Objective: To determine morphological and biological control as well as toxicity and quality of life (QoL) of men with localized prostate cancer (PCa) treated with MRI-guided focal boost radiotherapy. Material and Methods: 30 patients with PCa and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e604b2be83d471a991f35d635a28738c
https://doi.org/10.1259/bjr.20210683
https://doi.org/10.1259/bjr.20210683
Autor:
Jon Cacicedo, Alfonso Gomez-Iturriaga, Ainhoa Arana Gonzalez, A. Ezquerro, F. Couñago, M. Marban, P. Minguez, Francisco Casquero, Lorea Martinez-Indart, E. Mairata, A. Gil, A. Urresola, I. San Miguel, F. Suarez, D. Büchser
Publikováno v:
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 24, Iss, Pp 135-139 (2020)
Clinical and Translational Radiation Oncology, Vol 24, Iss, Pp 135-139 (2020)
Highlights • Prostate cancer T3a disease is a very heterogeneous entity. • Patients presenting major factors of T3a disease are at higher risk of biochemical failure and metastases.
MRI-detected T3a prostate cancer is a heterogeneous disease
MRI-detected T3a prostate cancer is a heterogeneous disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edbc56d01eca30effc40032f4e4ab1c5
https://doi.org/10.1016/j.ctro.2020.08.002
https://doi.org/10.1016/j.ctro.2020.08.002
Autor:
V. Morillo, Olga del Hoyo, D. Büchser, Juan Pablo Ciria, Francisco Casquero, Alfonso Gomez-Iturriaga, F. Suarez, Jon Cacicedo, Andere Frias, Lorea Martinez-Indart, Iñigo San Miguel
Publikováno v:
Journal of Medical Imaging and Radiation Oncology. 64:859-865
Introduction To assess pain response rate (RR) and quality of life (QoL), in patients with moderate/severe neuropathic pain (NP) due to bone metastasis (BM) undergoing palliative 3D radiotherapy plus tapentadol. Methods We conducted a prospective mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a760fb4d12873523cc22a7f13ceb91f7
https://doi.org/10.1111/1754-9485.13088
https://doi.org/10.1111/1754-9485.13088
Autor:
Jose Luis Lopez-Guerra, O. del Hoyo, Jon Cacicedo, A. Barcena, F. Suarez, D. Büchser, B.D. Delgado, Alvaro Gonzalez, Francisco Casquero, Alfonso Gomez-Iturriaga, I. San Miguel, R. Ortiz de Zarate, F. Andere, Lorea Martinez-Indart, E. Mayrata
Publikováno v:
Radiotherapy and Oncology. 152:S529-S531
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76fa90a6ce0a317436b5d222ca8a0a83
https://doi.org/10.1016/s0167-8140(21)01011-2
https://doi.org/10.1016/s0167-8140(21)01011-2
Autor:
Felipe Couñago, Vérane Achard, E. Mayrata, Alba González, Rafael Medina, Filippo Alongi, Alfonso Gomez-Iturriaga, D. Büchser, Marina Marban
Although dose escalation protocols have improved biochemical control in prostate cancer radiotherapy, 10–45% of patients will experience disease recurrence. The prostate and seminal vesicles are the most frequent site of the first relapse. Traditio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5a8425a123c2f00e3f55426dc0e775a
http://hdl.handle.net/11379/547680
http://hdl.handle.net/11379/547680
Autor:
Gallardo, E., Garcia, D. Büchser, Placido, L. Regis, Gonzalez, E. Rios, Perez, A. Marco, Agut, C. Moretones
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S1229-S1229
Autor:
Iñaki Zabalza, D. Büchser, Roberto Llarena, Arkaitz Carracedo, Alba González, Iratxe Fernández, Jorge García-Olaverri, Claudia Manini, Rafael Pulido, A. Ezquerro, José I. López, Alfonso Gomez-Iturriaga, A. Urresola
Publikováno v:
Journal of Personalized Medicine
Volume 10
Issue 4
Journal of Personalized Medicine, Vol 10, Iss 265, p 265 (2020)
Volume 10
Issue 4
Journal of Personalized Medicine, Vol 10, Iss 265, p 265 (2020)
The clinical parameters and the histological and immunohistochemical findings of a prospective protocolized series of 27 prostate carcinoma patients with oligometastatic disease followed homogeneously were analyzed. Lymph nodes (81.5%) and bones (18.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867a16ddfb2ca8be137db3e277d077b7
http://europepmc.org/articles/PMC7761807
http://europepmc.org/articles/PMC7761807